Mast cells (MC) are important cellular components of the immune network in diverse organs. The skin MC has likewise been implicated in IgE-and complementmediated cutaneous reactions. Such reactions supposedly involve specific cell surface membrane receptors. In this study, the cell surface marker profile of human skin MC was established using monoclonal antibodies (MoAb) against defined CD antigens. MC were isolated from juvenile foreskin (n ⍧ 55) and adult mammary skin (n ⍧ 5). The reactivity of MC with MoAb was assessed by a combined toluidine blue/immunofluorescence staining technique. Confirming our previous analyses on lung MC, foreskin MC reacted with MoAb against CD9, CD29, CD33, CD43, CD44, CD45, CD46, CD51, CD54, CD55, CD58, CD59, CD61, and CD117 (c-kit). Foreskin MC were also recognized by MoAb to CD47, CD48, CD49d, CD53, CD60, CD63, CD81, CD82, CD84, CD87, CD92, M ast cells (MC) are proinflammatory effector cells of the immune system (Schwartz, 1985; Galli, 1993) . These cells produce several vasoactive and other biologically relevant molecules (Lewis and Austen, 1981; Serafin and Austen, 1987; Gordon et al, 1990) . Under certain conditions and in response to diverse stimuli, MC release their products and thereby can participate in a number of pathophysiologic processes (Siraganian, 1985; Galli, 1990 Galli, , 1993 Dvorak, 1991; Walsh et al, 1991) .
release (Ishizaka and Ishizaka, 1984) . MC also express a number of adhesion receptors and recognition molecules, as well as cell surface receptors for complement activation products (Valent and Bettelheim, 1992) .
During the past few decades substantial evidence for the existence of subpopulations of MC has been accumulated (Befus et al, 1985; Irani et al, 1986; Enerbäck, 1987; Kitamura, 1989) . Human MC can be subclassified based on expression of the two proteolytic MC enzymes, tryptase and chymase (Irani et al, 1986) , expression of cell surface membrane receptors (Füreder et al, 1995) , response to activating ligands, and distinct ultrastructural properties (Dvorak, 1991) . A number of studies suggest that MC heterogeneity is an organ-specific phenomenon. In particular, major differences were found when phenotypic and functional properties were analyzed and compared in human cutaneous and ''noncutaneous'' MC. Specifically, cutaneous MC, but not lung MC, express large amounts of the mast cell specific enzyme chymase (Irani et al, 1986) . Furthermore, juvenile foreskin MC release their mediators in response to C5a, morphine, and substance-P, whereas lung MC were found to be unresponsive against these agonists (Benyon et al, 1987; Lawrence et al, 1987; Füreder et al, 1995) . We have recently described that MC derived from human foreskin, as opposed to lung or other visceral organs, express CD88, the receptor for the complement activation product C5a (Füreder et al, 1995) . These observations prompted us to look for additional biologic and antigenic differences between cutaneous and ''noncutaneous'' MC. For this purpose, we isolated human MC from juvenile foreskin, adult mammary skin, and lung tissue specimens, and analyzed the immunophenotypic and functional properties of these cells. a Foreskin and lung MC were purified and prepared as described in the text. A combined toluidine blue/immunofluorescence staining technique was applied to determine the reactivity of primary MC with MoAb. At least three MC preparations (three different donors) were analyzed for each individual MoAb. HMC-1 cells were analyzed by flow cytometry. The results are expressed as percentage reactive cells using a score system: ϩϩ, more than 90% of cells reactive; ϩ, 50%-90% of cells reactive; ϩ/-, 20%-49% of cells reactive; -/ϩ , 10%-19% of the cells reactive; -, less than 10% of cells reactive. Results obtained with lung MC and HMC-1 (CD25-130) were found to correspond to our previous data (Agis et al, 1996) .
MATERIALS AND METHODS

Monoclonal antibodies (MoAb)
A number of MoAb were used to immunophenotype MC. One part of MoAb were obtained from the IVth (Vienna 1989 ), Vth (Boston 1993 ), or VIth (Kobe 1996 International Workshops and Conferences on Human Leukocyte Differentiation Antigens. A specification of MoAb (CD, Ig subclass) is provided in Tables I-VIII. The following MoAb were purchased: A2MRα-2 and A2MRβ-1 (both CD91) from American Diagnostica (Greenwich, CT); S-HCL3 (CD11c), L138 (CD13), and L60 (CD43) from Becton Dickinson (San Jose, CA); and HD39 (CD22) from Behring (Marburg, Germany). The MoAb VNR147 (CD51), W-CAM-1 (CD54), G3 (anti-tryptase), B7 (anti-chymase), and human myeloma IgE were from Chemicon (Temecula, CA); F10-44-2 (CD44) was from Cymbus Bioscience (Southampton, U.K.); and MoAb 366 (CD13) was from Coulter Clone (Hialeah, FL). The MoAb JC/70A (CD31), PD7/26 ϩ 2B11 (CD45), PG-M1 (CD68R), and F8/86 (against von Willebrand factor, vWF) were purchased from Dako (Glostrup, Denmark); MoAb M10 (CD121a) and 1H7 (CD121b) were from Genzyme (Cambridge, MA); and BL4 (CD4), BEAR 1 (CD11b), K20 (CD29), 2E1 (CD32), QBEND10 (CD34), SZ2 (CD42b), J4-48 (CD46), J4.57 (CD48), HP2B6 (CD49a), HP2/1 (CD49d), AMF7 (CD51), 84H10 (CD54), and E124.2.8 (anti-IgE) were from Immunotech (Marseilles, France). The MoAb MEM-102 (CD48) was from Monosan (Uden, Netherlands), and WM15 (CD13), 2F3 (CD15s), 2H5 (CD15s), HIB22 (CD22), FLI8.26 (CD32), M-B371 (CD37), HIT2 (CD38), GoH3 (CD49f), IA10 (CD55), H19 (CD59), 68-5H11 (CD62E), DREG-56 (CD62L), JS-81 (CD81), A59 (CD89), and 9F5 (anti-IL-3Rα/CD123) were from Pharmingen (San Diego, CA). A MoAb against GM-CSFRα (CD116) was from Santa Cruz Biotechnology (Santa Cruz, CA), the anti-C5aR MoAb S5/1 and W17/1 (CD88) were from Serotec (Oxford, U.K.), and MoAb RFB4 (CD22) was from Southern Biotechnology (Birmingham, AL). The MoAb LAM-89 (antilaminin) and BA-4 (anti-elastin) were purchased from Sigma (St. Louis, MO). The anti-c-kit MoAb YB5.B8 (CD117) was kindly provided by Dr. L.K. 
HML-1α HML-1 IgG2a ---a Foreskin MC and lung MC were enriched and analyzed as described in the text. For the score of antibody reactivity see the footnote to Table I . Results obtained with lung MC and HMC-1 were found to correspond to our previous data (Agis et al, 1996) . VNR, vitronectin receptor. 
a For score and specifications see the footnotes to Tables I and II. Results obtained with lung MC and HMC-1 were found to correspond to our previous data (Agis et al, 1996) . Ashman (University of Adelaide, Australia), and MoAb 1A2.C5 (CD117) was kindly sent by Dr. H.J. Bühring (University of Tübingen, Germany).
Other reagents and buffers Collagenase type II was purchased from Sebak (Suben, Austria), fetal calf serum was from Hyclone (Logan, Utah), and Lglutamine, penicillin/streptomycin, gentamycin, and fungizone were from Gibco Life Technologies (Gaithersburg, MD). Recombinant human (rh) SCF, as well as rhIL-1, rhIL-2, rhIL-4 through rhIL-11, rhIL-13, and rhIL-15 were from Peprotech (Rocky Hill, NY), rhIL-3 was from Sandoz (Vienna, Austria), rhIL-12 was from R&D Systems (Minneapolis, MN), rhC5a, toluidine blue, protease type XXIV, and 3-amino-9-ethylcarbazole were from Sigma, and tris-(hydroxymethyl)-aminomethan was from Biomol (Hamburg, Germany). Fluorescein isothiocyanate-goat F(abЈ) 2 anti-mouse IgG and fluorescein isothiocyanate-goat anti-rat IgG were from Caltag Laboratories (San Francisco, 
a For definitions and score of antibody reactivity see the footnote to 
a For definitions and score of antibody reactivity see the footnote to Table I . Results obtained with lung MC and HMC-1 were found to correspond to our previous data (Agis et al, 1996) . CA) and human AB-serum from Sera Lab (Crawley Down, U.K.). Biotinylated horse anti-mouse IgG and avidin-biotin-peroxidase complex (ABC Elite kit) were from Vector Laboratories (Burlingame, CA). Biotinylated goat anti-mouse immunoglobulin and peroxidase conjugated streptavidin were purchased from Biogenex Laboratories (San Ramon, CA). Histamine release buffer (Immunotech) contained 20 mM PIPES, glucose (1 g per liter), and 1 mM CaCl 2 . One litre of Mg/Ca-free Tyrode's buffer contained 0.2 g KCl, 0.05 g NaH 2 PO 4 .H 2 O, 8.0 g NaCl, and 1 g glucose. Iscove's modified Dulbecco's medium was purchased from Gibco Life Technologies and RPMI 1640 medium from PAA Laboratories (Linz, Austria).
Preparation and culture of mast cells Foreskin was obtained from 55 children (age 2 mo to 16 y; median, 4 y; mean, 5 y) undergoing circumcision. Informed consent was obtained from parents in each case. Normal mammary skin was obtained from five adult females who underwent reduction surgery after informed consent was obtained. Resected skin specimens were transported to the laboratory immediately after resection. Cutaneous MC were isolated according to standard procedures (Füreder et al, 1995) . In brief, tissue was cut into small pieces and washed in Tyrode's buffer. Tissue fragments were incubated in collagenase type II (2 mg per ml) for 90-180 min at 37°C. After digestion, cells were recovered, washed, and examined for MC by toluidine blue staining. Isolated foreskin MC were cultured in RPMI 1640 medium supplemented with 10% fetal calf serum at 37°C for at least 12 h before being used in immunostaining or release experiments. Human lung MC were enriched from lung tissue obtained from patients with bronchiogenic carcinoma (n ϭ 24, after informed consent) using collagenase type II as described (Schulman et al, 1982; Valent et al, 1989a) . The human mast cell line HMC-1 was kindly provided by Dr. J.H. Butterfield (Mayo Clinic, Rochester, MN). HMC-1 cells were maintained in Iscove's modified Dulbecco's medium with 10% fetal calf serum and antibiotics at 37°C/5% CO 2 .
Evaluation of surface antigen expression Expression of cell surface antigens on primary MC was analyzed by combined toluidine blue/immunofluorescence staining (Valent et al, 1989a) . In brief, cells were preincubated in AB serum for 30 min, incubated with MoAb for 30 min (4°C), washed, and then exposed to second-step fluorescein-labeled goat F(abЈ) 2 IgG anti-mouse antibody for another 30 min (4°C). Cells were then fixed in 0.025% glutaraldehyde for 1 min, washed, and incubated with toluidine blue (0.0125%) for 8 min. After washing, cells were examined under bright-field and fluorescence-light (fluorescence microscope, Olympus, Vienna, Austria). At least 20 cells were analyzed for each individual MoAb. Antigen expression on HMC-1 cells was analyzed by flow cytometry on a FACScan (Becton Dickinson, Palo Alto, CA) as described (Agis et al, 1996) . All MoAb used were checked for cell reactivity and specificity during the VIth International Workshop and Conference on Human Leukocyte Differentiation Antigens (Kobe, 1996) .
In situ staining experiments Immunohistochemistry on paraffin-embedded tissue (juvenile foreskin, n ϭ 1) was performed as described previously (Hsu et al, 1981) . In brief, paraffin-embedded specimens were cut into 2 µm thin (serial) sections and mounted on silan-coated slides. Then, sections were dewaxed in xylol. For several antigens, the antigenicity was enhanced either by pretreating the sections with 0.05% protease type XXIV, or by high temperature antigen unmasking using a microwave oven as described (Shi et al, 1991; Cattoretti et al, 1993) . Protease digestion was performed in case of staining for CD31 (JC/70A), CD51 (VNR147), CD54 (W-CAM-1), CD68R (PG-M1), CD117 (1A2.C5), vWF (F8/86), chymase (B7), laminin (LAM-89), and elastin (BA-4). Microwave oven heating was applied in case of staining for CD34 (QBEND10) and CD44 (F10-44-2). In case of staining for CD43 (L60), CD45 (PD7/26 ϩ 2B11), and tryptase (G3), sections were not pretreated. After each step, the sections were rinsed twice in 0.05 M Tris-buffered saline (pH 7.5). Sections were incubated with ''first-step'' MoAb at room temperature for 1 h, incubated with biotinylated ''second-step'' antibodies for 30 min at room temperature, and then incubated with avidin-biotin-peroxidase complex or peroxidase-conjugated streptavidin for 30 min at room temperature. Bound antibody was visualized with 3-amino-9-ethylcarbazole for 5-10 min. Slides were counter-stained with Mayer's Haemalaun for 3 min.
Histamine release experiments Histamine release was performed on skin MC (foreskin, n ϭ 11; adult skin, n ϭ 2) according to published techniques (Valent et al, 1989b) . In case of IgE-dependent release, skin MC were preincubated with IgE (myeloma derived) for 3 h at 4°C, washed, and resuspended in histamine release buffer. Then, skin MC were exposed to antiIgE MoAb E124.2.8 (0.01-10 µg per ml) for 30-45 min. Skin MC were also exposed to rhSCF (0.01-100 ng per ml), rhIL-1-4 (100 U per ml), rhIL-5-13, and rhIL-15 (each 100 ng per ml), or rhC5a (10-1000 ng per ml). Cytokines were added to MC for either 45 min (n ϭ 4) or 90 min (n ϭ 2) in 96 well microtiter plates (Costar, Cambridge, MA) at 37°C. The ''priming-effect'' of 01a, 01b, 01c, 002, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 012, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024, 025, 027, 028, 030, 031, 034, 035, 036, 037, 038, 039, 040, 041, 042a, 045RO, 049a, 049b, 049f, 050, 052, 056, 062E, 062L, 062P, 064, 065, 066, 067, 068, 069, 070, 071, 072, 073, 074, 075, 076, 077, 078, 079, 080, 085, 086, 089, 090, 091, 093, 094, 095, 096, 101, 103, 104, 105, 106, 108, 114, 115, 116, 118, 121a, 121b, 122, 123, 126, 127, w128, 130, 131, 132, 134, 135, w136, w137, 138, 139, 140a, 140b, 141, 142, 143, 144, w145, 146, 148, w150, 152, 153, 154, 155, 156, 162, 164, 165, 166 Lung MC ϩϩ 009, 029, 043, 044, 046, 047, 048, 053, 055, 058, 059, 063, 081, 082, 084, 092, 097, 098, 099, 117, w149, 151 ϩ 033, 049d, 050, 051, 054, 157, 061, 069, 087, 090, 107b, 093, 102, 108, 124, 001b, 001c, 002, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024, 025, 027, 028, 030, 031, 032, 034, 035, 036, 037, 038, 039, 040, 041, 042a, 049a, 049b, 049f, 056, 057, 062E, 062L, 062P, 064, 065, 066, 066b, 068, 070, 071, 072, 073, 074, 075, 076, 077, 078, 079b, 080, 083, 085, 086, 088, 089, 091, 094, 095, 096, 101, 103, 104, 105, 106, 114, 116, 118, 120a, 120b, 121a, 121b, 122, 123, 126, 127, w128, 130, 131, 132, 134, 135, w137, 138, 139, 140a, 140b, 141, 142, 143, 144, w145, 146, 148, w150, 152, 153, 154, 155, 156, 162, 164, 165, 013, 029, 032, 037, 040, 043, 044, 046, 047, 048, 050, 053, 054, 055, 058, 059, 063, 066, 081, 082, 084, 087, 092, 097, 098, 099, 117, 147, w149, 151, 155 ϩ 033, 049d, 072, 088, 095, 116, 130, 164, 049a, 051, 052, 061, 071, 101, 108, 118, 157, 049b, 060, 064, 118, 120a, 120b, 121b, 122, 001b, 001c, 002R, 003, 004, 005, 006, 007, 008, 010, 011a, 011b, 011c, 012, 014, 015, 015s, 016, 017, 018, 019, 020, 021, 023, 024, 027, 028, 030, 031, 034, 035, 036, 038, 039, 041, 042a, 049f, 056, 062E, 062L, 062P, 065, 066b, 068, 069, 070, 073, 074, 075, 076, 077, 078, 079b, 080, 083, 085, 086, 089, 090, 091, 093, 094, 096, 102, 103, 104, 105, 106, 114, 121a, 123, 124, 126, 127, w128, 131, 132, 134, 135, w136, w137, 138, 139, 140a, 140b, 141, 142, 143, 144, w145, 146, 148, w150, 153, 154, 156, 163, 166 a For definitions and score of antibody reactivity see the footnote to Table I . Results obtained with lung MC and HMC-1 correspond to our previous data (Füreder et al, 1995; Agis et al, 1996) . a In situ detection of antigens in sections of paraffin embedded foreskin. The applied immunohistochemistry technique is described in the text. The applicability in paraffin embedded sections and the specificity of the MoAb were tested by evaluating their reactivity with reference cells known to express the respective antigen.
b In the case of CD51, a bone marrow section was used to control reactivity with reference cells. the cytokines on IgE-dependent mediator release of MC (foreskin) was also analyzed. For this purpose, MC were first exposed to IgE (see above), then to rhSCF (100 ng per ml), rhIL-9-13 (100 ng per ml each), rhIL-15 (100 ng per ml), or control medium for 15 min at 37°C, and then stimulated with various concentrations of anti-IgE MoAb E124.2.8 (0.1-10 µg per ml) for 30 min. After incubation with agonists, cells were centrifuged at 4°C and the cell-free supernatants recovered by aspiration. Liberated histamine was measured by a commercial radioimmunoassay (Immunotech). Total histamine in cell suspensions was quantitated after cell lysis in distilled water and freeze thawing. Histamine release was expressed as percentage of total histamine.
RESULTS
Sufficient amounts of MC are detectable in tissue dispersates
Mast cells were isolated from juvenile foreskin (n ϭ 55), adult mammary skin (n ϭ 5), and lung (n ϭ 24) by incubation in collagenase. As determined by toluidine blue staining of cytospin preparations, the percentage of MC in the primary foreskin cell suspensions ranged between 1% and 9%, between 0.5% and 3% in adult mammary skin cell suspensions, and between 1% and 16% in the lung cell suspension. Based on their morphology, the isolated cutaneous MC appeared to have good viability. In line with their ''viable'' morphology, the skin MC showed a low baseline level of spontaneous histamine release (mean Ϯ SD, 2.8 Ϯ 1.8%; range, 0.8%-6.8%, n ϭ 11).
Cutaneous MC express c-kit Expression of cytokine R on skin MC was analyzed by using MoAb directed against previously or more recently clustered antigens. Like MC from human lung, cutaneous MC (from foreskin and adult skin) were found to react with MoAb to stem cell factor receptor c-kit (CD117). In contrast, foreskin MC did not react with MoAb to other cytokine R, including IL-3Rα (CD123), GM-CSFRα (CD116), and G-CSFR (CD114) ( Table I) . No difference was found when the cytokine receptor profile of skin MC was compared with the well-established phenotype of lung MC. Table I shows a summary of staining results obtained with MoAb against cytokine receptors.
Skin MC express a unique profile of adhesion receptors (R)
The distribution and function of various cells in the tissues supposedly is associated with expression of distinct adhesion receptors. In this study, the adhesion receptor profile of skin MC was established and compared with the R profile of lung MC and HMC-1. Adhesion R detectable on foreskin MC were CD29 (common β-chain of β1 integrins), CD49d (VLA-4α), CD51 (vitronectin-R[VNR]-α), and CD61 (VNRβ) ( Table II) . Moreover, foreskin MC were found to react with MoAb against CD54 (ICAM-1), CD9 (p24), CD43 (leukosialin, ICAM-1-ligand), CD44 (Pgp-1, hyaluronate-R), and CD58 (LFA-3) ( Tables III-V) . Novel adhesion-related CD antigens detectable on MC were CD147 (neurothelin) and CD151 (PETA-3) ( Table V) . The ICAM-3 antigen (CD50) that is expressed on lung MC and MC from other visceral organs (Agis et al, 1996) was not detectable on foreskin MC or MC of adult mammary skin (Table IV) . Thus, using seven different MoAb against ICAM-3, we were not able to obtain a staining signal with foreskin MC or MC of adult mammary skin in our toluidine blue/immunofluorescence double staining technique, whereas the same CD50 clones produced a significant reactivity with lung MC in parallel experiments ( Table IV) . The HMC-1 cell line was also found to react with CD50 MoAb (Table IV) . A number of adhesion receptors were neither detected on cutaneous MC nor detected on lung MC (Tables II-V) . Overall, cutaneous MC express a similar, but not identical profile of surface adhesion receptors when compared with lung MC. In contrast to lung MC, skin MC do not express significant amounts of ICAM-3.
Cutaneous MC express FcεRI and FcγRII
Basophils and mast cells reportedly express high affinity IgE binding sites on their surface; however, these cells may express additional Ig-binding sites as well. In this study, human skin MC (foreskin and adult skin) were found to react with three different MoAb directed against the FcγRII (CD32), namely IV.3, 2E1, and FLI8.26. In contrast to MC from foreskin or adult skin, lung MC did not react with MoAb against FcγRII. Neither skin MC nor lung MC were found to react with MoAb against FcαR (CD89), FcεRII (CD23), FcγRI (CD64), or FcγRIII (CD16). Table VI shows a summary of staining results obtained with MoAb against Ig receptors.
Skin MC express various complement and virus receptors
A number of recently defined CD antigens have been identified as binding sites for both complement-related and viral antigen. Likewise, the membrane cofactor protein CD46 has recently been identified as a receptor (R) for the measles virus. In line with our previous observations (Füreder et al, 1995) , foreskin MC were found to express membrane cofactor protein CD46 and the decay-accelerating factor, an echovirus receptor. Moreover, foreskin MC were found to react with MoAb against the membrane attack complex inhibitory factor. The ICAM-1 antigen CD54, a well-known rhinovirus receptor, is also expressed on cutaneous MC. Cutaneous MC did not react with MoAb against CD4 (HIV-R), CD21 (EBV-R ϭ CR2), CD49b (echo-V-1-R), CD50 (ICAM-3 ϭ HIV-1-R), or CD155 (polio-V-R). Foreskin MC were also found to lack significant amounts of CR1 (CD35), CR3 (CD11b), and CR4 (CD11c).
In line with our previous data (Füreder et al, 1995) , MoAb against the C5aR (CD88) were found to react with MC from human juvenile foreskin. By contrast, these MoAb did not stain human MC derived from adult mammary skin. Thus, the C5aR is differentially expressed on various MC populations, but does not indicate organ-specific heterogeneity of MC.
Cutaneous MC express distinct novel CD antigens Novel CD antigens detectable on foreskin MC (and lung MC) were CD147 (neurothelin), the platelet-endothelial cell tetraspan antigen-3 (PETA-3 ϭ CD151), CDw149 (MEM-133), and CD157 (BST-1 ϭ bone marrow stromal cell antigen-1). In addition, foreskin MC were found to react with MoAb against members of the transmembrane 4 superfamily, namely CD53 (gp32-40), CD63 (ME491), and CD81 (TAPA-1), which are all involved in cellular signalling. A summary of surface staining results obtained with all MoAb is depicted in Table VII. Cutaneous MC express CD antigens in situ To confirm expression of CD antigens in cutaneous MC in situ staining was performed using human juvenile foreskin. The experiments were performed using serial sections stained with anti-tryptase versus other MoAb. In these experiments most cutaneous (tryptase ϩ ) MC stained positive for chymase (MC TC ). Moreover, cutaneous tryptase ϩ MC were recognized by MoAb to c-kit, CD43, CD44, CD45, CD51, CD54, and CD68R. No reactivity of MC with MoAb against CD31, CD34, vWF, or laminin was found. Table VIII shows a summary of in situ staining results.
Cutaneous MC are responsive against distinct agonists In order to determine the functional significance of surface receptor expression on skin MC, histamine release experiments were performed. Incubation of foreskin MC with c-kit ligand rhSCF for 45 min was followed by specific mediator secretion in three of 10 donors. In these three responsive donors, rhSCF (100 ng per ml) raised the amount of liberated histamine from 0.8% (spontaneous release) to 9.6%, from 1.6% to 11.8%, and from 2.8% to 23.5%. In the other donors, no measurable release was elicited by rhSCF. In all donors examined, incubation of MC with anti-IgE resulted in substantial increase of histamine release above control [anti-IgE, 1 µg per ml, 20.3 Ϯ 8.8% versus control, 2.6 Ϯ 1.5% (mean Ϯ SD, n ϭ 3)]. Preincubation of foreskin MC with rhSCF for 15 min prior to anti-IgE activation (30 min) resulted in an enhanced liberation of histamine when compared with preincubation in control medium (Fig 1) . The other cytokines (IL-9, IL-10, IL-11, IL-12, IL-13, IL-15) did not modulate the releasability of MC. Moreover, none of the cytokines tested except SCF, induced histamine release from MC in the absence of anti-IgE. According to previous observations, rhC5a induced concentrationdependent secretion of histamine from juvenile foreskin MC [rhC5a, 1000 ng per ml, 90 min, 11.5 Ϯ 6.7% versus control, 1.7 Ϯ 1.0% (mean Ϯ SD, n ϭ 3)]. By contrast, rhC5a did not induce histamine release from mammary skin MC (n ϭ 3) above control (not shown).
DISCUSSION
Mast cells are potent effector cells of the immune system. These cells express a number of inflammatory mediators in their granules and can release their products upon stimulation by IgE-dependent or IgEindependent stimuli. Depending on the tissue environment and condition, MC express distinct patterns of surface receptors for various active ligands. In this study we have determined the receptor profile of human cutaneous MC. The results of our study show that cutaneous MC differ from other MC by expressing substantial amounts of FcγRII, and by lack of detectable ICAM-3/CD50. Expression of the C5aR, previously felt to be a marker of skin MC (indicating organ-specific MC heterogeneity) was detectable on foreskin MC, but not on MC isolated from adult mammary skin tissue or human lung.
Human MC reportedly express receptors for SCF, but do not express significant amounts of other cytokine binding sites (Valent and Bettelheim, 1992; Agis et al, 1996) . In line with this notion, foreskin MC were found to react with MoAb against c-kit, but did not react with MoAb against a number of other cytokine receptors including IL-3Rα, GM-CSFRα, G-CSFR, and IL-6R. Thus, human skin MC express an identical cytokine receptor profile when compared with other MC types. The failure of cutaneous MC to respond to cytokine ligands other than SCF in our histamine release experiments is compatible with this result. On the other hand, we cannot exclude expression of very low amounts of interleukin receptors that could not be detected by the staining technique applied. The possibility that the isolation technique caused a loss of cytokine surface receptors could be excluded, because other cells (non-MC-lineage cells) clearly reacted with the respective MoAb in the same cell suspensions.
An interesting observation was that cutaneous MC, but not lung MC, react with MoAb against FcγRII (CD32). This Ig receptor has been implicated in certain immune responses and has been detected on human basophils (Stain et al, 1987) and mouse mast cell progenitors (Daeron et al, 1992; Lantz and Huff, 1995) . Furthermore, the FcγRII has recently been localized on human uterine MC by Guo et al (1992) . In our previous studies, however, we were not able to localize the FcγRII on MC (Valent et al, 1989a) . This divergency may be explained by the different MoAb used, differential expression of epitopes, or different antibody titers. An alternative (more reasonable) explanation seems to be MC heterogeneity. Another explanation for the differential expression of the FcγRII on MC would be a different activation status of MC, or a different expression of this receptor at various stages of cell maturation. Interestingly, the immature MC line HMC-1 also expressed FcγRII. An unresolved question is the functional role of the FcγRII on human skin MC. One attractive hypothesis would be that this binding site is involved in the regulation of mediator secretion, as has been suggested for the basophil Fcγ receptor.
Mast cells express a characteristic profile of adhesion receptors (Valent and Bettelheim, 1992; Agis et al, 1996) . In particular, lung MC express CD29 (β chain of β1 integrins), CD49d (VLA4α), CD54 (ICAM-1), CD51 (VNRα), and CD61 (VNRβ) (Valent and Bettelheim, 1992; Agis et al, 1996) . The ICAM-3 antigen (CD50) has also been detected on human lung MC (Agis et al, 1996) . By contrast, however, we were not able to show a significant binding of CD50 MoAb to MC derived from juvenile foreskin or adult mammary skin in this study. These observations suggest that, in contrast to lung MC, skin MC lack (or express only very low amounts of) CD50. The functional significance of this organ-specific heterogeneity of MC is not known. The other adhesion receptors analyzed showed an identical cellular distribution when lung MC and skin MC were compared with each other.
In order to confirm expression of antigens in skin MC, in situ staining experiments were performed. In these experiments we were able to show in situ expression of CD43, CD44, CD45, CD51, CD54, and CD117 (c-kit) in cutaneous MC. These results are in line with our earlier experiments performed on cardiac MC (Sperr et al, 1994; Bankl et al, 1995) . The MC enzymes tryptase and chymase were also detectable in foreskin MC. Thus, corresponding to previous findings (Irani et al, 1986 ) the vast majority of cutaneous MC were found to coexpress chymase and tryptase (MC TC ). Only few MC appeared to express tryptase, but not chymase (MC T ). MC expressing chymase but not tryptase (MC C ) were not detectable.
Recently a number of novel CD antigens have been defined, and for several of these novel CD markers a specific functional role has already been presented. Likewise, several novel adhesion related molecules, like selectin ligands (such as PSGL-1/CD162), vascular antigens, or cadherins, have been defined as CD molecules. So far, however, little is known about the distribution of novel CD molecules on human mast cells. The results of this study suggest that MC from human foreskin (and lung) express the adhesion related molecules CD147 (neurothelin) and CD151 (PETA-3), as well as CD149 and CD157 (BST-1). Whether these novel CD antigens play a role in the function, biology, or patho-physiology of human mast cell, remains to be determined.
The C5a receptor reportedly is expressed on human foreskin MC, but is not detectable on human lung MC (Füreder et al, 1995) . In this study, we analyzed the expression of CD88 on MC derived from lung, foreskin, and adult human mammary skin. As expected, foreskin MC were recognized by MoAb against C5aR, whereas lung MC did not react with CD88 MoAb. Unexpectedly, however, the C5aR was not detectable on MC derived from adult human skin. This observation argues against an organ-dependent distribution of this receptor on MC. Rather it seems as if this antigen is differentially expressed on various types of MC depending on the maturation stage or activation of cells. In this regard it is noteworthy that synovial MC in patients with rheumatoid arthritis, but not in osteoarthritis, express significant amounts of C5aR (Kiener et al, 1998) . Another important aspect is that the HMC-1 cell line, which is immature and intrinsically activated by a c-kit point mutation, expose substantial amounts of C5aR/CD88 (Füreder et al, 1995) . An alternative explanation for the differential expression of C5aR on foreskin MC versus adult mammary MC could be that cutaneous MC in different anatomical regions express different phenotypes.
The C5a receptor (CD88) has been implicated in C5a-induced cell migration and histamine release. In particular, we have recently shown that the rhC5a-induced histamine release in foreskin MC is inhibitable by preincubating the MC with a blocking CD88 MoAb (Füreder et al, 1995) . In this study, foreskin MC (expressing CD88) released histamine in response to rhC5a, whereas lung MC and MC derived from adult human mammary skin (both lacking CD88) did not release histamine in response to rhC5a. These results support the hypothesis that the effect of C5a on histamine release in MC is dependent on C5aR expression.
A number of studies have shown that MC are responsive against IgE-dependent stimuli and distinct cytokines. In our experiments, both rhSCF and anti-IgE induced histamine release from human cutaneous MC; however, whereas anti-IgE induced release of histamine in all donors analyzed, rhSCF induced histamine release in a minority of the patients only. This is in contrast to other human MC types (lung, heart, uterus) that showed a clear (direct) response to SCF in all donors tested (Sperr et al, 1993) . Interestingly, a minor response of cutaneous MC against SCF has also been described by Columbo et al (1992) ; however, although rhSCF did not cause direct histamine secretion in most donors, the cytokine was found to strongly upregulate the responsiveness of MC against IgE-dependent cell activation in all MC preparations. By contrast, the other cytokines tested neither induced histamine release nor enhanced the IgE-dependent releasability of MC. These observations are in line with previous studies on lung MC and with the failure to detect significant amounts of cytokine receptors (other than SCF receptor) on foreskin MC.
The exact pathophysiologic role of cutaneous MC in various skin diseases is not completely understood; however, a number of potentially important molecular and cellular interactions have been described and some of the (novel) CD molecules may be of interest in this respect. Likewise, several CD molecules have recently been identified as virus binding sites. Specifically, CD46 is known as measles virus receptor (Dorig et al, 1993) , and CD54 as rhinovirus receptor (Staunton et al, 1989) . The results of our studies suggest that human skin MC express receptors for the measles virus (CD46), rhinovirus (CD54), echovirus (CD55), and African swine fever virus (CD59). Whether these MC binding sites are involved in the pathophysiology of infectious diseases of the skin remains to be determined.
In summary, our data show that cutaneous MC express a similar phenotype when compared with lung MC or other human MC types; however, distinct surface antigens seem to be expressed differentially on MC populations. Thus, in contrast to other MC, human skin MC express large(r) amounts of FcγRII (CD32) and lack CD50. These observations support the concept of human MC heterogeneity. 
